Cytonus Therapeutics expands C-suite as it transitions to a clinical stage company
SAN DIEGO, CA – Cytonus Therapeutics, Inc., a biotherapeutic company developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes™, announced today that Mickey Kim, MD, MBA has joined the company as Chief Business Officer.
In addition, Cytonus has added Sherry M. Carty, PhD, as Director of Intellectual Property and Karen Markham has been promoted to Chief Administrative Officer.
Dr. Kim brings significant corporate development, strategy, innovation and management experience. Dr. Kim was the Senior Vice President of Corporate Development and Head of Global Products at CareDx, Inc., where he led mergers and acquisitions, business development and collaboration activities. He also was the general manager of the company’s global kitted diagnostic business with offices in Australia, Sweden and the U.S.
“I’m very excited to add Dr. Kim to our management team as we grow Cytonus and establish the Cargocyte as a best-in-class drug delivery platform,” said Cytonus’ Chief Executive Officer and cofounder, Remo Moomiaie-Qajar, MD “His expertise, insight and experience in the biotech industry is important as we transition into a clinical stage company and continue to add to our partnerships.”
Dr. Kim led commercialization activities, as Senior Vice President of Research and Commercialization at Inova Health System, and applied genomics activities, as President of the Inova Translational Medicine Institute. Prior to Inova, he was a member of MedImmune/AstraZeneca’s Partnering & Strategy Leadership Team, a healthcare venture capitalist and a strategy consultant with McKinsey and Company.
Dr. Kim earned his Medical Doctor degree from the Northwestern University Medical School, his Master of Business Administration degree from the J.L. Kellogg Graduate School of Management, Northwestern University, and his Bachelor of Arts degree from the University of Chicago.
Dr. Carty has over 20 years of experience in intellectual property, bringing a wealth of experience as a patent leader fostering the success of start-ups, mid-sized companies and large multinational corporations. Dr. Carty earned a PhD in Biochemistry at Duke University and a BS in Biochemistry at Virginia Tech, where she was named the 2016-2017 Distinguished Alumni for Biochemistry.
Ms. Markham has been promoted to Chief Administrative Officer at Cytonus, where she oversees all administrative functions. Prior to joining Cytonus in 2021, Ms. Markham worked at the LEGO group, focusing on human resource information systems and serving on their Human Resources Strategic Planning Committee. She served as Chief Operating Officer at the law firm Robinson Donovan, PC. She also was Vice President of Administration and Vice President of Operations for the largest Ace Hardware co-op, where she managed 300+ employees in 32 stores across 7 states.
“In the past several years, we have focused on generating animal data that demonstrates the importance of our unique drug delivery approach,” said Dr. Moomiaie-Qajar. “As we expand the use of the Cargocytes with clinical collaborations, our new additions to our management team will help us build partnerships and grow in this very exciting time for our company.”
About Cytonus Therapeutics, Inc.
Cytonus is a San Diego-based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases, and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable “off-the-
shelf” therapies.
For more information, we invite you to us on LinkedIn and on Twitter “X” at: @CytonusTx.
Contact: press@cytonus.com
Statements in this news release other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products, and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words “believe,” “expect,” “aim,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.
